Recent news from 24dunia

Search results for  

cipla drug price list 

 ( 1-10 )
Sort by: Relevance |   Date

Cipla board approves retirement of M K Hamied

Drug firm Cipla Ltd on Thursday approved the retirement of executive vice chairman M K Hamied with effect from March 31,...
Source : Ndtv |
Category : Others

Cipla inks pact with Merck

Cipla has entered into an agreement with MSD to market the latter’s anti-HIV drug raltegravir in the country.This is the first time that Cipla is entering into a strategic partnership with a multinational drug company. MSD is the trade name of Merck & Co., Inc.Under the India-specific arrangement, Cipla will have a non-exclusive licence to market, promote and distribute MSD’s raltegravir 400mg tablet...
Source : Telegraphindia |
Category : Business | City : Mon

Drug price regulator runs into vanishing cos

India's drug price regulator has a unique problem. As it moves to revise the prices of medicines, it has found that the manufacturers of as many as 55 of them have simply gone missing."There is no information available for 55 random formulations and we may exclude them from the list of price fixation," CP Singh, chairman, Drug price watchdog National Phar maceutical Pricing Authority (NPPA) told HT.On...
Source : Yahoo Finance |
Category : Personal Finance | City : New Delhi

Get cheaper medicines from today

Your medicine bill will come down substantially from today, thanks to aruling to reduce prices of prescription drugs as instructed by the National Pharmaceutical Pricing Authority (So, starting December 25, more then 620 formulations of 348 essential bulk drugs under the national list of essential medicine would be sold at much cheaper rates.It is expected that prescription drugs price will get reduced...
Source : Times Of India |
Category : City | City : Lucknow

Cipla appoints Sameer Goel as India head

Drug major Cipla on Monday announced the appointment of Sameer Goel as its country head - India, effective immediately.Mr Goel, who comes to Cipla from GlaxoSmithKline (GSK), will be reporting to the company's managing director and global CEO Subhanu Saxena."This appointment signals the continuation of Cipla's strategy of strengthening the highly experienced senior management team and showing our strong...
Source : Ndtv |
Category : Others | City : New Delhi

Cipla posts net profit of Rs 358 crore in Q2

Drug major Cipla on Wednesday reported a consolidated net profit of Rs 358.06 crore for the quarter ended September 30, 2013.The company had registered a net profit of Rs 487.95 crore for the corresponding period a year ago, it said in a statement."Current year figures include the relevant results of Cipla Medpro and its subsidiaries from the date Cipla Medpro became subsidiary of the company and ...
Source : Ndtv |
Category : Others | City : New Delhi

Proposal on generic medicines gathers dust in UP

working on implementing drug price negotiation to popularise the use of generic (affordable) medicines, the Uttar Pradesh government is yet to open up to the idea. There is ambiguity in the state at all the levels despite chief ministerA generic drug may be defined as a drug product that is comparable to brand or reference listed drug product in dosage form, strength, route of administration, quality...
Source : Times Of India |
Category : City | City : Thiruvananthapuram

NPPA reduces prices of 63 vital drugs

Pharmaceutical Pricing Authority (NPPA) has revised prices of 63 drugs which include mainly life-saving drugs as well as anti-cancer, anti-viral and anti-infection medicines. The NPPA has decreased rates of most drugs by 15 to 50% but the prices of some drugs have been cut by as much as 66%. In some cases, however, a marginal rise in the cost of some medicines has been witnessed.The cost of paclitaxel...
Source : Times Of India |
Category : City | City : Ahmedabad

Cipla's net profit dips over 26% in Q2

Drug major Cipla's consolidated net profit for the July-September quarter dipped significantly by 26.6% to Rs 358 crore following low margins at its subsidiary Cipla Medpro....
Source : Times Of India |
Category : Business

Cipla to Market MSD's Raltegravir in India

UrologyMumbai-based pharmaceutical company Cipla announced that it has entered into an India-specific strategic partnership with Merck's Indian unit, MSD Pharma, to market the company's anti-HIV drug raltegravir in the country.Raltegravir is currently being marketed by MSD in India under the brand name Isentress for treating HIV-1 infection in adult patients. According to the agreement, Cipla will...
Source : Medindia |
Category : Health